Life sciences company Neogen (NASDAQ: NEOG) reported Q1 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 4.4% year on year to $211.2 million. The company’s full-year revenue guidance of $858.5 million at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $0.09 per share was 68.8% above analysts’ consensus estimates.

Is now the time to buy NEOG? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Neogen’s first quarter results were shaped by contrasting trends across its business lines. Management cited continued core growth in the Food Safety segment, particularly in the United States, while acknowledging significant supplier-driven disruptions in the Animal Safety business. CEO Mikhael Nassif noted, “We encountered several supplier challenges stemming from third-party manufacturers that unfortunately had a meaningful impact on our Animal Safety business.” The company responded by strengthening supplier qualification processes and implementing operational improvements to support reliability and efficiency.

Looking ahead, Neogen’s updated guidance reflects ongoing transformation efforts centered on commercial execution, innovation, and operational streamlining. Management is focused on accelerating new product development—especially in Petrifilm—and expects in-house manufacturing to boost margins in coming quarters. CFO Bryan Riggsbee highlighted the company’s cautious approach given persistent supply chain volatility and rising logistics costs, stating, “We are maintaining our adjusted EBITDA guidance in light of these headwinds and remain focused on long-term efficiency.” Neogen remains committed to leveraging its broad portfolio and refining its go-to-market approach as it navigates a dynamic market environment.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong Food Safety execution and the negative impact of third-party Animal Safety supply issues, while emphasizing ongoing transformation efforts.

• Food Safety core growth: Neogen’s Food Safety segment delivered another quarter of core growth, underpinned by strength in indicator testing and culture media. The company saw particularly robust performance in the U.S., with CEO Mikhael Nassif describing this as a milestone toward achieving above-market growth.
• Supplier disruptions in Animal Safety: Management detailed that disruptions from third-party manufacturers, including raw material shortages and production site transitions, meaningfully affected Animal Safety revenues. These supply-side issues were identified as temporary but significant headwinds.
• Operational efficiency initiatives: The company advanced its transformation strategy by focusing on process standardization and supply chain automation. Initiatives included validating Petrifilm manufacturing equipment and transitioning to a centralized planning model supported by AI-enabled logistics tools.
• Commercial leadership changes: Neogen appointed Tammi Ranalli as General Manager of Global Food Safety and Joe Freels as Chief Commercial Officer. These leaders are driving a revamped global go-to-market strategy, emphasizing resource allocation toward high-impact markets and solutions-based selling.
• Divestiture of genomics business: The sale of the genomics unit, expected to close in the second quarter of fiscal 2027, is anticipated to be accretive to margins and free up capital for debt reduction. Management views the transaction as supportive of a more focused product portfolio and improved profitability.

Drivers of Future Performance

Management’s outlook for the year is shaped by ongoing supply chain improvements, targeted investments in innovation, and cost discipline amid persistent external headwinds.

• Petrifilm innovation and manufacturing: Bringing Petrifilm production in-house is expected to provide margin expansion and agility in creating custom SKUs for new customer segments. Management believes this will drive incremental growth, especially as new R&D capabilities accelerate product development.
• Supply chain stabilization: Efforts to strengthen supplier management, reduce inventory, and streamline logistics are expected to improve cost structure and service reliability. However, management cautions that elevated freight and input costs may persist in the near term, impacting short-term profitability.
• Strategic resource reallocation: The company’s shift toward metric-driven performance tracking and reallocation of sales resources aims to support higher-margin products and key markets. Management expects these moves to enhance long-term growth, though initial costs related to transformation will be absorbed in the near future.

Catalysts in Upcoming Quarters

In the coming quarters, key catalysts will include (1) the pace of Petrifilm manufacturing transition and its impact on margins, (2) the resolution of supply chain challenges within the Animal Safety segment, and (3) progress from commercial leadership changes and the new solutions-based selling approach. Execution on these fronts, along with sustained innovation in Food Safety products, will be central to Neogen’s ability to deliver on its transformation plan.

Neogen currently trades at $10.08, down from $10.34 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.